Novo Nordisk A/S (NYSE:NVO) is a top pick among cheap healthcare stocks for 2026, with an analyst reaffirming a ‘Buy’ rating and $62 price target, indicating a 29% upside potential. The company will launch its diabetes drug Ozempic in India, a strategic move to tap into the growing weight-loss market.

With nearly 60% of analysts giving Novo Nordisk A/S (NYSE:NVO) a ‘Buy’ rating and a median price target of $62.01, the stock has a 29.57% upside potential. Established in 1923, the Denmark-based company specializes in pharmaceutical products, focusing on diabetes, obesity care, and rare diseases.

While Novo Nordisk A/S (NYSE:NVO) shows promise as an investment, some AI stocks may offer higher potential and lower risk. For those seeking undervalued AI stocks with growth potential, consider exploring opportunities outside of the healthcare sector.

Read more at Yahoo Finance: Analysts See Upside In Novo Nordisk A/S (NVO) Driven By Diabetes And Obesity Trends